home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  August 25, 2019
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[1] [3] [4] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Z] 521 active entries


An SBO Company

Phone: +1-(604)-945-8408
Fax: +1-(604)-941-9022


In the field of GMO Technologies there are these possibilities: (1) basic research in biomedicine (R&D), (2) therapeutics in healthcare and pharma, (3) animal feeds, food, energy or biofuels and environmental remediation and (4) bioengineering (polymers and ICE fermentation with a temperate or cold-adapted polar type microbiome; see: scientific literature).

To mitigate the movements against GMO type technologies, especially the food supply at SkyeBlue, we are using the following approaches: 1) plant cropping using GEdited with crossbacking using protoplasmic fusion which we are exclusively announcing here at SkyeBlue, 2) energy biocrops that are also GEdited with crossbacking using protoplasmic fusion but are biosafely protected from pollination specifically in the case of marine grasses (XL variety) (and solving this problem involving pharma application on land cropping) with secondary plant alkaloids, 3) and food processing such as polenta, higher-performing medicinal milk products and health-performing lower cholesterol eggs using cell filtration and/or DNAase treatment before packaging and storage appropriately as 'processed GMO-free'. To the best of our knowledge we not only just fulfilled our seal of approval to the public for offering: "the best and latest biotech" has to offer but believe this will be characteristic of more 'prize-worthy' performance and "do" at SkyeBlue, and 4) a direct-applied method in situ either in silage, per os in rumen or on the skin of animals like the mammary gland for improving silage, digestion and mastitic control, respetively using gene silencing control with protein nucleic acid (PNA) - B12 as carrier of the gene silencer.

Together with the prize-worthy method suggested above of GEditing and crossback breeding with protoplasmic fusion are the current furious activity of other researchers searching for significant motifs in their DNA research using modern bioinformatics. 

We are also currently investigating other biomedical advances in the health fields of: mental health and aging (gerontology) and related conditions. Our approach is to help define aetiology from a developmental standpoint of both the nervous system and the rest of the body and its function in daily living. 

With mRNA assays of TFs with genetic expression there is an area for drug discovery referred to, involving body weight/composition.  It is proposed that tested proprietary natural extracts be used with in situ biopsy using implants/microsurgical techniques with muscle representing lean body mass (LBM), the central nervous system (CNS) hypothalamic centre for satiety and fat thermogenic tissue against a background baseline of TFs in cell tissue assays. This has predisposed us to further research implicating nutraceutical AAs like HIS (histidine) in animal livestock production in class domesticated and game animals and at various stages of their growth and development. 

Approaches include future possibilities with mind-body psychoactives with putative roles of neurocrine factors in catecholamine and folate metabolism and possible roles in increased metabolic rate and health and longevity factors (the state-of-the-art in anti-aging research at this time involves approaches such as the discovery of human gene products SIRT 1-7 which control energy metabolism and cell survival which interact with nutritionals such as resveratrol in wine and with whom GlaxoSmithKline at the time of release of this story was pursuing research on efficacy trials II on more effective drug agents compared to resveratrol for diabetes II and inflammatory disease although other diseases such as aging with cancer and heart disease are also involved; research is being investigated at the Harvard Medical School and conjointly with UNSW Medical School), biopharmaceutical mood-altering functional, cognitive enhancing and kinesiologic therapeutics with possible developmental and geriatric applications, including links between exercise therapy and the onset of dementia and neurocrine deconditioning and anti-addiction therapies.

It is enticing to think that there are now direct linkages metabolically between aging/degenerative disease states and metabolism as with the gene products mentioned above and that, as we have espoused here, use of nutritionals can be a further avenue to discover or develop drugs that can enhance longevity and/or slow the aging and its disease processes. 

There are parallels seen between fructan metabolism vis-a-vis Vit D metabolism with cholesterolemia and cardiovascular health, blood sugar levels, insulinemia and colon digestive tract health including oncogeneisis and leaves open the possibility of the role of endocrine factors in metabolism. The author at Skye Blue has conducted preliminary research on lanosterol functionality and synthetic reactivity and sequencing. A proposed schema for converting lanosterol back to its C-13 labelled derivative with roughly estimated yields was presented in an undegraduate seminar discussing methodologies which were adopted from the previous literature in principle and which were further adapted using organic chemical principles by the principal research worker (see below).  Further research should study reactivity of steric derivatives of lanosterol to cholesterol and study of the differential reactivity of the ring system of the sterol molecule and the discovery to how drug candidates react to metabolic targets in intestines, bone, liver and kidney. Drugs can act in feedback inhibition (FBI) as 'enzyme agonists' as analogues to Vit D as theorized.  

The latest news which has again renewed the debate of inflammation (see below) and research uncovering mechanisms to diseases such as inflammation implicated with cancer and Alzheimer's is a drug that treats both skin T-cell lymphoma and Alzheimer's called by the trade name Targetrin (R) (bexarotene) that activates the surface protein and which produces ApoE which breaks down beta amyloid plaque (unlike Alzheimer's e4 allele) and improves cognitive function in mice to be tested further in human trials. Bexarotene acts by presumably activating ApoE allele variants (viz. e2 and e3 allele of which at least one is carried in 16% and 95% of the Caucasoid population, while in 27% of the population at least 1 e4 allele occurs which results in considerable debilitation in terms of onset and progression of Alzheimer's). The inflammation response by last reports is highly implicated in the onset itself of Alzheimer's. A hypothesis we are putting forth at Skye Blue of bexarotene's recent find as to a mechanism is via cell signaling pathways with cell surface receptor binding and intracellular nuclear factors [also termed transcription factors, TFs (see above)] signaling as one would be led to think involved with inflammation and that inflammation's genetic products have been directly implicated with cancer (viz. apoptosis, proliferation, angiogenesis, invasion, metastasis). The immune response, inflammation and cancer share common paths of cellular communication in terms of cell signalling implying common factors in their aetiology with the inflammation response. Genetic counselling or diagnosis and gene therapy might be called for as an interventive in at least 27% of the Caucasoid population, for example as was indicated unless, of course, other interventives are found for the disease response and its symptoms and causes.

Aging is a given process with demographic change which begs the question of allied healthcare delivery in our area or region in the world and inspired the idea here at SkyeBlue for university or community colleges a medical based lifestyle care and interventive program similar to the nursing profession in geriatric care called as a whole the associates degree (3-yr.), the Gerontological Care Programme using in a case study for Kwantlen Polytechnic University (KPU) these ff.: 1) "Psyche" (cognitive therapy & psychiatric care), 2) the conventional Nursing programme and 3) their current Gerontological-based recreation or activity programme. Wonderful specialties or career outlooks can arise: 1) Kinesiology & Cognitive Therapy care support in multiple level care facilities, 2) Psychology in Geriatric support care and 3) Geriatric support care in the medical field of Neurology, all running through providing a skeletonon which to build on total geriatric care delivery in the medical health field.

SKYEVIEWResearch leading to technological breakthroughs: research on new anti-psychotic/psychotropic drugs that improve mental cognition (i. e. focusing, reasoning, memory, energy level) in schizophrenia/bipolar and developmental disabilities and social affect/mood and withdrawal; the research studying the interactions between nutrients in feed and the genetics of animal body mass and composition and further drug research for growth in animal production; the role of adult stem cell and cancer research with phagocytotic/cytotoxic immune cells against tumour cell activity; new conjectures on energy metabolism and expenditure or excercise; neurocrine factors and the endocrine system and cell survival or eventually related to studies on longevity with identified genes, have begun.  

SKYEVIEW: New phytobotanical think-tank launched at Skye Blue and the future prospects for markets of phytobotanical nutritionals and organo-sourced production and marketing for more sustainability, decreased lability, and better logistical delivery. Skye Blue's involvement with phytobotanicals that are, for example, psychotropics, viz. activating to brain function including insight, reasoning and memory, such as the tea botanical from two plants from the Peruvian jungle called a concoction: ayahuasca (a-ya-wat-ka) has already been studied by medical science to activate the neocortex, amygdala and insula (insular cortex) which are involved with personality and insight, impulses and emotions and early memories.  At this time, therapeutic uses of this phytobotanical are for treatment of drug addiction including the addiction itself over several months therapy. It is striking that there are complex structure-function relationships between the human brain and substances of plant origin.  This may beg the question of how close homologies vs variants exist with structure-function of neuroreceptors that are targets for such drugs.  Classes of receptors and their ligands will be discovered it is predicted including their homologues. The search for variants and better acting drugs, for example, using the psychotropic ayahuasca will involve mutating cultures of nerve cells and doing receptor-ligand binding studies and studying what structural-functional relationship exist between both and how to articulate and improve drug structure and its function. (See: http://hum-molgen.org/companies/profile.php3/3811-botanie-baie-7.)

SKYEVIEW: A new publication outlines the demand for foods in the future with complex carbohydrates reviewing new and proposed research in fortifying these plant crops (e.g. cereals, fruits and vegetables, orphaned crops as the sweet potato, bananas and cassava) and their health-conferring benefits regards inflammatory response and occupational-related diseases such as atherosclerosis, diabetes and cancers. We are publishing this new paper on the links between chronic inflammation, immunonogeneic response and disease states, such as diabetes, atherosclerosis and cancer, and their links to both nutritionals, Vit D and fructans, in the lower gut, a clue to the linkage between the two factors and other diseases also linked to the prolonged chronic elicitation or aggravation of the inflammation response. We invite editorial oversight on the investigation of the inflammation process including published/unpublished research findings on this exciting and growing field in health research.  

SKYEVIEW:  At Skye Blue we have shown interest in psychotropy and psychotropic, anti-psychotic drugs used in treating both bipolar disorders and schizophrenia.  Certain older psychotropics improve thinking process, presumably by improving recall functions, focus, associative and cognitive functions.  Adducively, these drugs help thinking process and is consistent with the observation that it lowers anxiety levels or works as an anti-anxiety medication and improves the 'ushering' of sleep and regularizes sleeping patterns in disturbed sleep which accompanies mental health disorders (e. g. apo-methoprezine).  Also, certain anti-psychotics helps with symptoms such as lack of energy and social withdrawal or depression (e. g. Abilify, Zeldox). Psychotropy may be equilibrated with drugs based on a 'titre' in brain-damage or mental retardation or it  is speculated with underperforming 'normal' individuals and geriatric patients including the aged, those suffering from dementia and Alzheimers.  Much more research on newer psychotropics (e. g. Abilify, Zeldox, Invega) are needed including their potential side-effects (e. g. physical affect, tardive dyskinesia). It has been oberved in 'normal' individuals undergoing psychotropy in a psychosocial rehabilative setting with such residents that thinking and daily work habits and outcome is more 'orthogonal', i. e. they work more congruently with others and their work output is increased and of better, and in other cases, of remarkably better quality.

SKYEVIEW: The recent find with newer drug anti-psychotic interactions in the brain between, for e. g., Invega (R) and Abilify(R), improves cognitive performance parameters such as awareness, alertness, problem solving, recall and associative thinking. These may apply to both mental health rehabilative programmes as well as the elderly with geriatric multi-care care programmes. 

SKYEVIEW: Cognitive enhancers are coming now into the fore and are also within theories of 'plasticity' of brain structure and function.  At Skye Blue we have always speculated as to whether cognitive enhancers (e. g. processing, problem solving, storage, and retrieval functions) earlier on have further down the line could have a neuroprotective effect, a new frontier of research in neuroscience, against Alzheimers or other dementias. Although we speculate that dementias are a type of developmental disorder of the brain to protect against onset and any progression. The brain progresses in stages as it is hypothesized so we at Skye Blue have put forward these new concepts, viz.: cognitive enhancement, neuroplasticity, neurodevelopmental disorders and neuroprotective interventions. The recent studies of Reelin proteins in the brain that can reverse the overt signs of abberant cellular anatomical plaque and amyloid-beta fibril entanglements can 'reverse' this clinical phenotype of Alzheimers via the Reelin cell signaling pathways and recovery of cognate cognitive deficits. (Cf. further to: http://www.ub.edu/web/ub/en/menu_eines/noticies/2014/03/010.html). 

SKYEVIEW: It has been recently speculated at SkyeBlue as to the lower gut's status as an endocrine / immuno centre protecting against onset of cancers waiting to be mined for biopharma, for e. g. bioactive peptides. We believe in exploring possibilities as evidence weighs heavily towards further speculation: VitD, fructan, and now certain milk food proteins, e. g. bovine casein and lactoferrin, have been demonstrated to protect against cancer of the lower bowel or colon (large intestines). Do they 'just so happen' to act together, we speculate, or is this an organ and system or probable 'centre', as we call it, reflecting the fact that the organ system is involved in protecting or preventing against colon and other cancers -with yet to be discovered requisite endocrine / immuno functions, protecting against and acting after its onset. 

The ongoing affair of Philippines with the Life Sciences industry and including foreign owned multi-nationals is predicted to take effect with both Co-op industry development and venture capitalist investments in v. valuable R&D research with institutes in universities and multinationals. It appears the 'old menace' presented to the favoured communits parties (NLFP and NPA) of American involvements in the case of the Island region of Negros could be dissipated by both job creation with Co-ops and demarcations made by the PNP of Philippine National Police and Special Armed Forces (SAF) which are being sent as we speak to the Island to eradicate effectively all presence of communist troops and/or win them over together with negotiations in the capital Manila with both political parties deciding in effect via manifesto to support the new order being prepared by Pres. Roa Duterte with new efforts to add monies to government coffers from oil exploration (we predict industry activity in areas of oil refineries, transportation fuel manufacturing and plastics for domestic use and export); the recent agreement with mainland China has been a 60:40 split between Manila and Beijing, from the Western Philippine Sea. We look forward to more news and development from this new front in Philippines foreign affairs.

Selected Categories:
Product Company   Service Company
- General
- Services
- Communications

Last update of this entry: August 14, 2019

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2019 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.